DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Toxicity To Various Agents - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Toxicity To Various Agents (146)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include toxicity to various agents. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 146   Next >>

Possible Cyclophosphamide side effects in

Reported by a physician from Spain on 2012-08-06

Patient:

Reactions: Skin Toxicity, Sudden Death, Hepatic Failure, Encephalitis, Cytomegalovirus Colitis, Pneumonia Pneumococcal, Neurotoxicity, Death, Multi-Organ Failure, Metastasis, Cardiotoxicity, AIDS Dementia Complex, Pseudomonas Infection, Toxicity To Various Agents, Staphylococcal Infection, Pneumonia Herpes Viral, Neutropenia, Escherichia Infection, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: given on day 1 of the 3 week cycle
    Indication: Lymphoma AIDS Related

Doxorubicin HCL
    Dosage: given on day 1 of the 3 week cycle
    Indication: Lymphoma AIDS Related

Mabthera
    Dosage: given on day 1 of every 3 week cycle (prior to chop)
    Indication: Lymphoma AIDS Related

Prednisone TAB
    Dosage: given for 5 days
    Administration route: Oral
    Indication: Lymphoma AIDS Related

Vincristine Sulfate
    Dosage: given on day 1 of 3 week cycle.
    Indication: Lymphoma AIDS Related

Other drugs received by patient: Hydrocortisone; Cytarabine; Methotrexate



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-31

Patient:

Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Chemoradiation
    Indication: Hodgkin's Disease

Cyclophosphamide
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Prednisone
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-30

Patient:

Reactions: B-Cell Lymphoma Refractory, Toxicity To Various Agents, Treatment Failure, Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-26

Patient:

Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Chemoradiation
    Indication: Hodgkin's Disease

Cyclophosphamide
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Prednisone
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: 100 mg on days 1-5 for chop and r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 375 mg/m2 on day 1 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Netherlands on 2012-07-16

Patient:

Reactions: Graft Versus Host Disease, Pulmonary Embolism, Toxicity To Various Agents, Polyneuropathy, Disease Progression, Death, Embolism Venous, Deep Vein Thrombosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 15 milligram/sq. meter

Adriamycin PFS
    Dosage: 9 milligram/sq. meter
    Indication: Multiple Myeloma

Cyclophosphamide
    Dosage: 1000 milligram/sq. meter
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: 40 milligram
    Administration route: Oral

Dexamethasone
    Dosage: 40 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Melphalan Hydrochloride
    Dosage: 200 milligram/sq. meter

Thalomid
    Dosage: induction therapy, 200 mg escalated to 400 mg, qd, with vte prophylaxis
    Administration route: Oral
    Indication: Multiple Myeloma

Thalomid
    Dosage: maintenance therapy, 50 mg qd, without vte prophylaxis
    Administration route: Oral

Other drugs received by patient: Neupogen; Mycophenolate Mophetil; Cyclosporine; Nadroparine



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-06

Patient:

Reactions: Dysphagia, Stomatitis, Gastrointestinal Toxicity, Gastrointestinal Inflammation, Toxicity To Various Agents, Gastritis, Oesophagitis, Colitis, Pharyngitis

Drug(s) suspected as cause:
Bortezomib
    Indication: Multiple Myeloma

Cisplatin
    Indication: Multiple Myeloma

Cyclophosphamide
    Indication: Multiple Myeloma

Dexamethasone
    Indication: Multiple Myeloma

Doxorubicin HCL
    Indication: Multiple Myeloma

Etoposide
    Indication: Multiple Myeloma

Lenalidomide
    Indication: Multiple Myeloma

Melphalan Hydrochloride
    Dosage: single dose of 200 mg/m2 and fractionated dose of 50 mg/m2 on days 1-4
    Indication: Multiple Myeloma

Thalidomide
    Indication: Multiple Myeloma



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Toxicity To Various Agents, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 on days 1-14 oral)
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: (30 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (500 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Diarrhoea, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 on days 1-14 oral)
    Administration route: Oral
    Indication: Breast Cancer

Fluorouracil
    Dosage: (600 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer

Methotrexate
    Dosage: (40 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Diarrhoea, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 oral)
    Administration route: Oral
    Indication: Breast Cancer

Fluorouracil
    Dosage: (600 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Methotrexate
    Dosage: (40 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Tamoxifen Citrate
    Dosage: (df (daily))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-02

Patient:

Reactions: Off Label Use, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Chronic Lymphocytic Leukaemia

Etoposide
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Indication: Chronic Lymphocytic Leukaemia

Oncovin
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Indication: Chronic Lymphocytic Leukaemia



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Toxicity To Various Agents, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 oral)
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: (30 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (500 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Diarrhoea, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 oral)
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: (30 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (500 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Depression, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 oral)
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: (30 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (500 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Tamoxifen Citrate
    Dosage: (df (daily))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Vomiting, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 oral)
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: (30 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (500 mg/m2 intravenous (not otherwise specified)
    Indication: Breast Cancer

Tamoxifen Citrate
    Dosage: (df (daily))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Toxicity To Various Agents, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 100 mg/m2, oral
    Administration route: Oral
    Indication: Breast Cancer

Fluorouracil
    Dosage: 600 mg/m2, intravenous
    Indication: Breast Cancer

Methotrexate
    Dosage: 40 mg/m2, intravenous
    Indication: Breast Cancer

Tamoxifen Citrate
    Dosage: df daily
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Pulmonary Embolism, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 100 mg/m2, oral
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 30 mg/m2, intravenous (not otherwise specified)
    Indication: Breast Cancer

Fluorouracil
    Dosage: 500 mg/m2, intravenous
    Indication: Breast Cancer

Tamoxifen Citrate
    Dosage: df daily
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Pulmonary Embolism, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 oral)
    Administration route: Oral
    Indication: Breast Cancer

Fluorouracil
    Dosage: (600 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Methotrexate Sodium
    Dosage: (40 mg/m2 intravenous (not otherwise specified))
    Indication: Breast Cancer

Tamoxifen Citrate
    Dosage: (df (daily))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29

Patient: female

Reactions: Renal Failure, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (100 mg/m2 on days 1-14 oral)
    Administration route: Oral
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: (30 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer

Fluorouracil
    Dosage: (500 mg/m2 on days 1 and 8 intravenous (not otherwise specified))
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-06-28

Patient: female

Reactions: General Physical Condition Abnormal, Drug Intolerance, Recurrent Cancer, Toxicity To Various Agents, Tongue Neoplasm Malignant Stage Unspecified, Metastases To Skin, Treatment Failure, Metastases To Pleura, Metastases To Bone, Metastases To Lung

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Arimidex
    Dosage: 1 dosage forms;
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2008-01-01
    End date: 2009-02-01

Aromasin
    Dosage: 1 dosage forms;
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2006-11-01
    End date: 2007-02-01

Cyclophosphamide
    Dosage: 4 courses
    Indication: Breast Cancer
    Start date: 2004-12-03
    End date: 2005-02-02

Doxorubicin HCL
    Dosage: 17 courses
    Indication: Breast Cancer
    Start date: 2007-08-27
    End date: 2009-11-05

Epirubicin Hydrochloride
    Dosage: 4 courses
    Indication: Breast Cancer
    Start date: 2004-12-03
    End date: 2005-05-02

Estracyt
    Dosage: 4 dosage forms;
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2009-12-03
    End date: 2011-01-01

Faslodex
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2007-02-01
    End date: 2007-05-01

Femara
    Dosage: 1 dosage forms;
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2005-04-01
    End date: 2006-11-01

Fluorouracil
    Dosage: 4 courses
    Indication: Breast Cancer
    Start date: 2004-12-03
    End date: 2005-02-02

Navelbine
    Dosage: 90mg on day 1 and 8, 4 courses
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2007-07-01
    End date: 2007-11-01

Navoban
    Dosage: 4 courses
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2007-07-01
    End date: 2007-11-01

Taxotere
    Dosage: 3 courses
    Indication: Breast Cancer
    Start date: 2005-03-08
    End date: 2005-04-19

Xeloda
    Dosage: 4 courses
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2007-08-01
    End date: 2007-11-01



Possible Cyclophosphamide side effects in

Reported by a physician from Italy on 2012-06-27

Patient:

Reactions: Death, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma, Chemotherapy

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Unspecifed Medications
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from France on 2012-06-27

Patient:

Reactions: Febrile Neutropenia, Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma, Thrombocytopenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Granulocyte Colony Stimulating Factor
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Dosage: on days 1-5, every 21 days for 6 cycles
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1, every 21 days for 6 cycles
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-06-27

Patient:

Reactions: Off Label Use, Toxicity To Various Agents

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Doxorubicin Hydrochloride
    Indication: Chronic Lymphocytic Leukaemia

Etoposide
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Indication: Chronic Lymphocytic Leukaemia

Oncovin
    Indication: Chronic Lymphocytic Leukaemia

Prednisone TAB
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Indication: Chronic Lymphocytic Leukaemia



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-27

Patient:

Reactions: Stomatitis, Dysphagia, Gastrointestinal Toxicity, Gastrointestinal Inflammation, Toxicity To Various Agents, Gastritis, Oesophagitis, Colitis, Pharyngitis

Drug(s) suspected as cause:
Bortezomib
    Indication: Multiple Myeloma

Cisplatin
    Indication: Multiple Myeloma

Cyclophosphamide
    Indication: Multiple Myeloma

Dexamethasone
    Indication: Multiple Myeloma

Doxorubicin HCL
    Indication: Multiple Myeloma

Etoposide
    Indication: Multiple Myeloma

Lenalidomide
    Indication: Multiple Myeloma

Melphalan Hydrochloride
    Dosage: single dose of 200 mg/m2 and fractionated dose of 50 mg/m2 on days 1-4
    Indication: Multiple Myeloma

Thalidomide
    Indication: Multiple Myeloma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22

Patient:

Reactions: Performance Status Decreased, Pain, Abdominal Pain Upper, Fatigue, Neutropenic Infection, Thrombocytopenia, Hallucination, Dyspnoea, Vomiting, Nausea, Hyperglycaemia, Haemoglobin Abnormal, Pancytopenia, Febrile Neutropenia, Toxicity To Various Agents, Haemoglobin, Neutropenia, Diffuse Large B-Cell Lymphoma, Cardiovascular Disorder, Leukopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Granulocyte Macrophage Colony Stim Factor
    Dosage: days 3-10
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: 6-8 cycles
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Anti-Emetics; Dapsone; Trimethoprim + Sulfamethoxazole



Possible Cyclophosphamide side effects in 55 year old male

Reported by a physician from Belgium on 2012-06-21

Patient: 55 year old male

Reactions: Bone Marrow Failure, Toxicity To Various Agents, Aplasia, Leukopenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 110 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-03
    End date: 2009-07-03

Cyclophosphamide
    Dosage: 460 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-03
    End date: 2009-07-05

Depocyt
    Dosage: 50 mg;inth
    Indication: Metastases To Meninges
    Start date: 2009-07-03
    End date: 2009-07-03

Folic Acid
    Dosage: 200 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-03
    End date: 2009-07-05

Methotrexate Sodium
    Dosage: 5500 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-02
    End date: 2009-07-02

Methylprednisolone
    Dosage: 100 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-02
    End date: 2009-07-05

Rituximab (Rituximab)
    Dosage: 693 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-01
    End date: 2009-07-01

Vincristine
    Dosage: 2 mg;iv
    Indication: Metastases To Meninges
    Start date: 2009-07-02
    End date: 2009-07-02



Possible Cyclophosphamide side effects in male

Reported by a individual with unspecified qualification from Netherlands on 2012-06-20

Patient: male, weighing 74.1 kg (163.0 pounds)

Reactions: Neoplasm Progression, Fall, Loss of Consciousness, Disease Progression, Multi-Organ Failure, Acute Myocardial Infarction, Decreased Appetite, Gastrointestinal Ulcer Haemorrhage, Faecal Incontinence, Toxicity To Various Agents, Pulmonary Sepsis, Lung Disorder, Cardiac Failure, Drug-Induced Liver Injury, Sensory Disturbance, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1430 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2010-11-11

Doxorubicin HCL
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2010-11-11

Mabthera
    Dosage: 710 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2010-11-11

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: 500 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2010-11-11

Vincristine
    Dosage: 1 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2010-11-11

Other drugs received by patient: Diclofenac Sodium; Diflucan; Cotrim; Piperacillin and Tazobactam; Valacyclovir Hydrochloride; Fenazepam; Valacyclovir Hydrochloride; Cotrim; Allopurinol; Omeprazole; Ondansetron; Fluconazole



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-14

Patient:

Reactions: Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Haematotoxicity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: it was performed in a group which was given r-chop for 14 days and r-chop for 21 days.
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from Germany on 2012-06-01

Patient:

Reactions: Respiratory Disorder, Pain, Myelodysplastic Syndrome, Pyrexia, Neoplasm, Death, Completed Suicide, Thrombocytopenia, Vomiting, Nausea, Anaemia, Acute Myeloid Leukaemia, Toxicity To Various Agents, Haematotoxicity, Hodgkin's Disease, Mucosal Inflammation, Accident, Alopecia, Gastrointestinal Disorder, Nervous System Disorder, non-Hodgkin's Lymphoma, Cardiovascular Disorder, Leukopenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: Hodgkin's Disease

Cyclophosphamide
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Prednisone TAB
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease

Other drugs received by patient: Radiotherapy



Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-31

Patient: 28 year old female

Reactions: Ovarian Atrophy, Blood Follicle Stimulating Hormone Increased, Uterine Disorder, Blood Luteinising Hormone Increased, Toxicity To Various Agents

Drug(s) suspected as cause:
Busulfan
    Dosage: 16 unk
    Indication: Bone Marrow Conditioning Regimen

Cyclophosphamide
    Dosage: 120 mg/kg
    Indication: Bone Marrow Conditioning Regimen



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017